Literature DB >> 15794853

Autoantibody activity in Waldenstrom's macroglobulinemia.

Marvin J Stone1, Giampaolo Merlini, Virginia Pascual.   

Abstract

Some monoclonal proteins from patients with Waldenstrom's macroglobulinemia (WM) or immunoglobulin (Ig) M monoclonal gammopathy of undetermined significance possess antigen-binding activity directed to autogenous or foreign antigens. These monoclonal IgM autoantibodies include cold agglutinins, mixed cryoglobulins, and antineural components. Because of the antigenantibody interaction, patients with these autoimmune syndromes often present with hemolytic anemia, mixed cryoglobulinemia, or peripheral neuropathy, respectively, at an earlier stage than patients with typical WM who do not have evident antibody activity. The presence of monoclonal macroglobulin autoreactive antibodies thus influences clinical presentation and natural history. Monoclonal IgM antibodies display polyreactivity to antigens of microbial origin in addition to autogenous antigens and may arise through T-independent as well as T-dependent pathways. Waldenstrom proteins with antibody activity appear to provide a link between autoimmunity, infection, and lymphoproliferative disease. Study of the antigens reacting with monoclonal IgMs may provide further insight into the pathogenesis of WM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794853     DOI: 10.3816/clm.2005.n.004

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN: 1526-9655


  3 in total

1.  Pathophysiology of Waldenström's macroglobulinemia.

Authors:  Marvin J Stone; Virginia Pascual
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 2.  Cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome.

Authors:  Shelly Pathak; Dorota Rowczenio; Samuel Lara-Reyna; Mark Kacar; Roger Owen; Gina Doody; Karoline Krause; Helen Lachmann; Rainer Doffinger; Darren Newton; Sinisa Savic
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.